Search

everythinglearnresearchcommunity

for

Search:↓

A 35-year-old male uses topical minoxidil, spironolactone, and microneedling for hair loss, with spironolactone prescribed based on a DNA test indicating poor response to finasteride and dutasteride. Despite concerns about the test's validity and spironolactone's side effects, he reports stable or improved hair condition and no low testosterone symptoms.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

The conversation discusses the cost-effectiveness of using premade RU58841 versus making it from powder for hair loss treatment. It also questions whether higher concentrations are more effective for women.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

Soy consumption may help prevent androgenic alopecia, but it can decrease sexual drive in some men. There is a connection between soy and androgenic alopecia, suggesting a potential protective effect.

The conversation is about hair loss treatment using topical minoxidil, finasteride, and arginine, showing noticeable progress in one month. The user suggests adding arginine serum for better results.

The conversation discusses hair regrowth using finasteride, minoxidil, biotin, and vitamin D over three months, with visible results. One person asks about the daily dosage of vitamin D and biotin.

Using Vitamin C serum after dermarolling may help with healing and hair health. The safety of additional ingredients like Glycerin, Propylene Glycol, Phenoxyethanol, Sodium Benzoate, and Sodium Metabisulfite in hair regrowth is questioned.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.